S. Korea to approve Viagra generics

Three South Korean pharmaceutical firms will soon be allowed to produce generic versions of the anti-impotence drug Viagra despite a row over patents, officials said Wednesday.

The Korea said generic products made by the three local firms have passed a "bioequivalence" test.

"The three firms are expected to get approval for production of Viagra generics probably this month or later," an official in charge of medicine tests told AFP on condition of anonymity.

"Our move has nothing to do with an ongoing patent row," he said, adding the watchdog is also expected to give the go ahead for more local firms.

Numerous domestic pharmaceutical firms have applied for approval to manufacture Viagra generics since it was introduced in in 1999.

US pharmaceutical giant Pfizer claims its patent, which involves using sildenafil, is valid until May 2014.

"Our patent covering the material is still valid," a Pfizer official in Seoul said, urging South Korean firms to recognise it.

Pfizer has yet to counter a lawsuit filed by CJ Cheiljedang, a domestic seeking to invalidate the patent.

"We plan to produce a generic Viagra regardless of the court's ruling, even if we have to compensate Pfizer in the future," an unnamed CJ Cheiljedang official told Yonhap news agency.

add to favorites email to friend print save as pdf

Related Stories

Drug firm GSK fined $2.6 million for collusion

Oct 24, 2011

South Korea's anti-trust agency has fined drugmaker GlaxoSmithKline three billion won ($2.6 million) for conspiring with a Seoul rival over the sale of drugs, an official said Monday.

Slovenia to launch generic version of Viagra

Jul 31, 2009

Krka, the biggest drugmaker in Slovenia, said Friday that its generic version of the impotency drug Viagra would be launched in September and priced 30 percent cheaper than the original.

Recommended for you

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

Tough-to-abuse formulation of oxycodone approved

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe pain when other ...

EU regulator: Morning-after pill OK for all women

Jul 24, 2014

(AP)—A commonly used morning-after pill is suitable for use by heavier women, the European Medicines Agency said Thursday after a review of the evidence sparked by the French manufacturer's declaration that the drugs didn't ...

User comments